Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05664152
Other study ID # MG1111_VAR_P0302
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date February 2023
Est. completion date June 2023

Study information

Verified date December 2022
Source GC Biopharma Corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: - Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) - Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 250
Est. completion date June 2023
Est. primary completion date April 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 12 Years
Eligibility Inclusion Criteria: 1. Healthy children aged 12 months to 12 years (inclusive) 2. Subject parent/legal representative willing to provide written informed consent and able to comply with the requirements for the study - Subject able to attend all scheduled visits and to comply with all study procedures 3. Negative history of Varicella and varicella vaccine 4. Subject in good health, based on medical history and physical examination 5. Having a readily identifiable place of residence in the study area, being available for the duration of trial participation, with means of telephone contact. Exclusion Criteria: 1. Subjects who have a history of Varicella or administration of varicella vaccine 2. Subjects who have hypersensitivity reactions to the component of this Investigational Product, such as gelatin 3. Subjects with untreated active tuberculosis 4. Subjects with a history of Guillain-Barre syndrome 5. Subjects who had received salicylates (aspirin, bismuth subsalicylates) within 4 weeks before administration of investigational product or those who are planning to receive salicylates within 42 days after administration of investigational drug. 6. Subjects who administered anti-viral drug within 4 weeks before administration of investigational product or those who are planning to receive anti-viral drug within 42 days after administration of investigational drug. 7. Subjects who have had an acute febrile episode (at least 38.00C) at some time during the 72 hours before administration of investigational product or those who had any symptom suspected to be allergy including systemic rash. 8. Currently receiving or received any investigational intervention within 30 days prior to the vaccination of study vaccine. 9. Subjects who have completed vaccinations within 4 weeks before enrolment or who are planning to administer other vaccines within 42 days after administration of investigational product. 10. Administered any blood product or intravenous immunoglobulin administration within 44 weeks prior to the vaccination of study intervention 11. Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg for subjects who weight more than 10kg and less than 2mg/kg/day for subjects who weight less than 10kg, or equivalent) within 12 weeks prior to the vaccination of study vaccine. 12. Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia. 13. Subject with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the study vaccine. 14. Subjects with a severe chronic disease or other clinically significant medical or psychological condition who are considered by the Investigator to be ineligible for the study. 15. Subjects who are pregnant or lactating at the day of screening. 16. Subjects who are planned to participate in another clinical trial during the present trial period.

Study Design


Intervention

Biological:
MG1111
BARYCELA inj.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GC Biopharma Corp

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of BARYCELA inj.: Solicited local and systemic reactogenicity The incidence and severity of immediate solicited local and systemic reactogenicity within 30-minute post vaccination
Primary Safety of BARYCELA inj.: The incidence and severity of solicited local and systemic AEs The incidence and severity of solicited local and systemic AEs during 7 days post vaccination
Primary Safety of BARYCELA inj.: Incidence and severity of unsolicited AEs The incidence and severity of unsolicited AEs during 42 days post vaccination
Primary Safety of BARYCELA inj.: Incidence of adverse event of special interest The incidence of AE of Special Interest (AESI): varicella-like rash. during 42 days post vaccination
Primary Safety of BARYCELA inj.: Vital signs Vital signs Day0(Pre vaccination), 42 days post vaccination
Primary Safety of BARYCELA inj.: Body temperature Body temperature; measured according to standard of care and thermometer instructions. Day0(Pre vaccination), 42 days post vaccination
Primary Safety of BARYCELA inj.: Complete physical examination Complete physical examination; performed at Screening/Enrollment (Day 0) and Final Visit(Day 42). Day0(Pre vaccination), 42 days post vaccination
Primary Safety of BARYCELA inj.: Symptom-directed physical examination Symptom-directed physical examination (if any symptoms); performed at other timepoints as indicated to assess changes from Screening Day0(Pre vaccination), during 42 days post vaccination
Secondary Immunogenicity of BARYCELA inj.: Geometric Mean Titer (GMT) Geometric Mean Titer (GMT) of antibody titer measured with gpELISA Prior to IP administration and 42 days post vaccination
Secondary Immunogenicity of BARYCELA inj.: Geometric Mean Fold Rise (GMFR) Geometric Mean Fold Rise (GMFR) Prior to IP administration and 42 days post vaccination
See also
  Status Clinical Trial Phase
Completed NCT01682109 - Palatability Testing of a New Paediatric Formulation of Valacyclovir Phase 4
Recruiting NCT05198570 - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Not yet recruiting NCT06409494 - Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years Phase 1
Recruiting NCT05604911 - Herpes Virus Infections in Kidney Transplant Patients
Recruiting NCT05532540 - Herpesvirus Immunology in Solid Organ Transplant Recipients - Liver Transplant Study
Completed NCT01689285 - Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Phase 1
Terminated NCT04081480 - Pharmacokinetics of Valacyclovir Oral Solution in Children N/A
Recruiting NCT04403139 - VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination Phase 4